LifeVantage Corporation has granted a total of 848,767 shares in equity awards to Terrence Moorehead, its newly appointed President and Chief Executive Officer, as an inducement material to his employment. The Board of Directors approved the awards on August 6, 2026, under the company’s 2026 New Employee Long-Term Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The move aligns executive compensation with long-term shareholder value through service-based and performance-based vesting conditions.

The award structure consists of two distinct components designed to retain leadership while driving specific financial outcomes. The first component comprises time-based restricted stock units (RSUs), while the second involves performance-based restricted stock units (PSUs) linked to operational targets. Both awards are subject to continued service with the company through their respective vesting dates.

Award Structure Details

The following table outlines the composition and vesting terms of the equity grants awarded to Mr. Moorehead:

The RSUs will vest in three equal annual installments beginning on the one-year anniversary of the August 6, 2026 grant date. This time-based vesting ensures retention over a three-year horizon regardless of short-term market fluctuations.

The PSUs carry higher potential value but are contingent upon achieving specific financial milestones. These units will vest over a three-year period based on the achievement of certain revenue and Adjusted EBITDA margin targets. This performance linkage ties a significant portion of the executive’s compensation directly to the company’s profitability and top-line growth objectives.

What the Numbers Show

The composition of the award reveals a strategic emphasis on performance-driven compensation. The PSUs represent approximately 64% of the total share count granted (540,123 out of 848,767 shares), indicating that the Board prioritizes meeting revenue and margin goals over simple tenure-based retention. By weighting the majority of the equity toward performance metrics, LifeVantage signals that future executive rewards are heavily dependent on delivering measurable improvements in Adjusted EBITDA margins and revenue growth.

LifeVantage Corporation (NASDAQ: LFVN) operates as an activation company focused on nutrigenomics, offering scientifically validated activators including the Protandim family of products, TrueScience Liquid Collagen, and the MindBody GLP-1 System. The company was founded in 2003 and is headquartered in Lehi, Utah.

LifeVantage Corporation has officially appointed Terrence Moorehead as its President and Chief Executive Officer, marking a key leadership transition for the health and wellness firm. Moorehead also joins the company's Board of Directors, solidifying his role in strategic oversight. This appointment finalizes a succession plan that was first disclosed to investors on April 16, 2026, ensuring continuity for the NASDAQ-listed entity.

The leadership change is significant for LifeVantage, which focuses on products designed to activate optimal health processes at the cellular level. By installing a new CEO and board member simultaneously, the company signals a unified approach to future strategy. The official start date confirms the operational shift previously communicated to the market.

Leadership Details

Terrence Moorehead assumes dual responsibilities as both the top executive and a governing board member. This structure allows for direct alignment between daily operations and long-term corporate governance. The appointment was not unexpected, as it had been publicly announced nearly two months prior.

Context of Appointment

LifeVantage Corporation (NASDAQ: LFVN) operates in the health and wellness sector. The company’s product portfolio is centered on cellular health activation. The transition of leadership is now complete, allowing the new management team to focus on executing the company’s business strategy without interim arrangements.

What This Means

The formalization of Moorehead’s role removes any ambiguity regarding executive authority at LifeVantage. For shareholders, this provides clarity on who is driving the company’s performance going forward. The simultaneous board appointment suggests that Moorehead will have immediate influence over major corporate decisions, rather than serving solely in an operational capacity.